Error message

  • Strict warning: Declaration of biblio_handler_citation::init() should be compatible with views_handler::init(&$view, &$options) in require_once() (line 2 of /home/www/chspr/sites/all/modules/biblio/views/biblio_handler_citation.inc).
  • Warning: htmlspecialchars() expects parameter 1 to be string, array given in check_plain() (line 1545 of /home/www/chspr/includes/bootstrap.inc).

Use of atypical antipsychotic drugs for schizophrenia in Maine Medicaid following a policy change

Use of atypical antipsychotic drugs for schizophrenia in Maine Medicaid following a policy change

Health affairs (Project Hope)Health.Aff.(Millwood), Volume 27, Issue 3, United States, p.w185 - 95 (2008)
Journal Article
Abstract

More than one-third of Medicaid programs and Medicare Part D plans use prior authorization (PA) policies to control the use of atypical antipsychotics (AAs). We used Medicaid and Medicare claims data to investigate how Maine's PA policy affected AA use, treatment discontinuities, and spending among schizophrenia patients initiating AA therapy. Patients initiating AAs during Maine's policy experienced a 29 percent greater risk of treatment discontinuity than patients initiating AAs before the policy took effect; no change occurred in a comparison state. AA spending was slightly lower in both states. Observed increases in treatment discontinuities without cost savings suggest that AAs should be exempt from PA for patients with severe mental illnesses.

Keywords